# Cannabis Use Behaviors and Associations with Home Cultivation and Perceived Accessibility among Secondary School Students in Songkhla, Thailand > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-cannabis-product-type-tracks-with-polysubstan-2026-10-09/ > **Published:** 2026-10-09T22:44:05-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T22:44:05-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic These three papers point in the same direction: cannabis use is not a single behavior, and route, setting, and access matter. In adults, a wider mix of cannabis products appears to travel with broader polysubstance use, which should prompt a more complete substance history rather than a narrow question about marijuana alone. In youth, ED visits and school-based use patterns remind us that access, home cultivation, and perceived availability can shape risk long before dependence is obvious. The practical move is to ask about product type, frequency, source, and co-use every time. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicClinical and policy analysis: Cannabis Use Behaviors and Associations with Home Culti. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42854091/) Table of Contents - [Cannabis Use Behaviors and Associations with Home Cultivation and Perceived Accessibility among Secondary School Students in Songkhla, Thailand](#Cannabis_Use_Behaviors_and_Associations_with_Home_Cultivation_and_Perceived_Accessibility_among_Secondary_School_Students_in_Songkhla_Thailand)[How to Interpret This Cannabis News & Regulatory Digest](#How_to_Interpret_This_Cannabis_News_Regulatory_Digest)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[What this means for patients](#What_this_means_for_patients) - [How to use this in practice](#How_to_use_this_in_practice) - [Safety signals to watch](#Safety_signals_to_watch) - [Policy implications](#Policy_implications) - [What future studies should answer](#What_future_studies_should_answer) - [Where the evidence is weakest](#Where_the_evidence_is_weakest) - [What caregivers should notice](#What_caregivers_should_notice) - [Bottom-line clinical takeaway](#Bottom-line_clinical_takeaway) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Cannabis Use Behaviors and Associations with Home Cultivation and Perceived Accessibility among Secondary School Students in Songkhla, Thailand A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us In a nationally representative 2023 NSDUH sample of adult cannabis users, product type and use variety tracked with other substance use. Smoking, vaping, eating or drinking, dabbing, drops or lozenges, topicals, pills, and other forms were each examined against cigarette, alcohol, cocaine, heroin, methamphetamine, inhalant, hallucinogen, and ecstasy use, and a higher cannabis modality count was consistently linked to more polysubstance use. The youth ED scoping review mapped cannabis related emergency visits in children and adolescents, and the Thai secondary school study linked cannabis use behaviors with home cultivation and perceived access among students in Songkhla. Why This Matters Different routes of cannabis use can signal different risk profiles, so a patient who uses multiple product types may need more careful screening for alcohol, nicotine, and other drug use. For adolescents, easier access at home or in the community can shape exposure, escalation, and ED presentations, which makes family counseling and storage practices part of harm reduction. Study SnapshotPost TypeCannabis News & Regulatory Digest using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesOctober 09, 2026Related Reading3 verified live CED Clinic internal linksUpdate 1Method of Use Matters: Cannabis (Moscrop-Blake et al., Substance use & misuse) [DOI: 10.1080/10826084.2026.2740516 | PMID: 42854091]Update 2Cannabis related Emergency Department (ED) (Crocker et al., BMC Emergency Medicine) [DOI: 10.1186/s12873-026-01800-8]Update 3Cannabis Use Behaviors and Associations (Thongwichian et al., Journal of Health Science and Medical Research) [DOI: 10.31584/jhsmr.20261449] Clinical Bottom Line This clinical and regulatory overview preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Context Across These 3 Updates This curated cannabis news & regulatory digest brings together 3 key developments across policy movements, regulatory milestones, and public health communications. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report. Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data. Update 1: Method of Use Matters: Cannabis Product Type and **Title & Source:** [Method of Use Matters: Cannabis Product Type and Polysubstance Use Among Adult Cannabis Users.](https://pubmed.ncbi.nlm.nih.gov/42854091/) (*Substance use & misuse*, 2026Oct09) **Lead Authors & Identifiers:** Kelsi Moscrop-Blake, Wanda E Leal. | **Primary Record:** DOI: 10.1080/10826084.2026.2740516 | PMID: 42854091 Content lane: **Evidence Check**. **Investigational Focus:** This study used the 2023 National Survey of Drug Use and Health, a large nationally representative sample of adult cannabis users in the United States. It asked whether eight cannabis product types and a modality variety scale were associated with use of cigarettes, alcohol, cocaine, heroin, methamphetamine, inhalants, hallucinogens, and ecstasy. **Key Findings & Primary Data:** The analysis found that cannabis product types were differentially associated with other substance use and with levels of polysubstance use. A greater number of cannabis products used was consistently associated with both more additional substance use and higher polysubstance burden. **Clinical Guidance:** In clinic, multiple cannabis product use should trigger a broader substance history, including nicotine, alcohol, stimulants, and other drugs. Route-specific counseling can be more useful than generic advice, because the pattern of use may reflect different risk contexts. **Study Boundaries:** This is observational survey research, so it cannot prove causation. Self-report, recall error, and confounding by severity of use or social environment may shape the associations. Update 2: Cannabis related Emergency Department (ED) visits in youth **Title & Source:** [Cannabis related Emergency Department (ED) visits in youth: a scoping review](https://doi.org/10.1186/s12873-026-01800-8) (*BMC Emergency Medicine*, 2026-10-08) **Lead Authors & Identifiers:** Candice E. Crocker, Ashley Francis, Chloe Hambly-LaPointe, Philip G. Tibbo. | **Primary Record:** DOI: 10.1186/s12873-026-01800-8 Content lane: **Clinical Evidence Update**. **Investigational Focus:** This scoping review mapped the literature on cannabis related emergency department visits in youth. The focus was on how cannabis presentations appear in children and adolescents, and what the existing evidence says about patterns of acute care use. **Key Findings & Primary Data:** The review identified the youth ED literature and organized the available evidence on cannabis related presentations. The study report here does not report pooled incidence, age-stratified rates, or a single dominant clinical syndrome, so the main value is in mapping the scope of the evidence base. **Clinical Guidance:** Youth cannabis ED presentations should prompt screening for intoxication severity, co-ingestants, and access at home or through peers. Families benefit from counseling on locked storage, product labeling, and rapid recognition of altered mental status, vomiting, anxiety, or unsafe behavior. **Study Boundaries:** A scoping review depends on the quality and heterogeneity of the included studies. Without pooled effect estimates or standardized case definitions, the findings are best used for framing clinical questions rather than estimating risk precisely. Update 3: Cannabis Use Behaviors and Associations with Home Cultivation **Title & Source:** [Cannabis Use Behaviors and Associations with Home Cultivation and Perceived Accessibility among Secondary School Students in Songkhla, Thailand](https://doi.org/10.31584/jhsmr.20261449) (*Journal of Health Science and Medical Research*, 2026-10-08) **Lead Authors & Identifiers:** Phonchai Thongwichian, Sawitri Assanangkornchai, Wit Wichaidit. | **Primary Record:** DOI: 10.31584/jhsmr.20261449 Content lane: **Clinical Evidence Update**. **Investigational Focus:** This school-based study examined cannabis use behaviors among secondary school students in Songkhla, Thailand, with attention to home cultivation and perceived accessibility. The question was how access-related factors relate to student cannabis behavior in a real-world adolescent setting. **Key Findings & Primary Data:** The study linked cannabis use behaviors with home cultivation and perceived accessibility among secondary school students. The summary does not provide exact prevalence, adjusted odds ratios, or dose-response estimates, but it clearly identifies access as a relevant correlate of use. **Clinical Guidance:** For adolescents, access questions belong in every substance history, including whether cannabis is grown at home or easy to obtain from family or peers. Prevention counseling should include parents or caregivers, because storage and household norms can shape exposure. **Study Boundaries:** This appears to be a cross-sectional school study, so it cannot determine whether access preceded use or followed it. Local laws, school context, and reporting bias may limit how far the findings generalize beyond Songkhla. How Strong Is This Evidence? The adult study draws from the 2023 National Survey of Drug Use and Health, which gives it strong population coverage and useful generalizability for U.S. adults. The youth ED review and the Thai school study add context from different settings, but their evidentiary weight depends on the quality of the underlying studies they summarized or the cross-sectional design they used. Where This Paper Deserves Skepticism The adult analysis is observational, so product choice may mark underlying risk tolerance, social setting, or prior substance use rather than cause it. The youth review likely inherits heterogeneity in case definitions, age bands, and ED coding, while the Thai school study cannot separate access from peer influence, family environment, or local policy effects. What This Paper Does Not Show These papers do not prove that any cannabis product type causes polysubstance use or emergency department visits. They also do not establish which specific prevention strategy, screening tool, or policy change will reduce harm in adults or adolescents. How This Fits With the Broader Clinical Conversation Cannabis research is moving away from broad yes or no exposure questions and toward route, potency, frequency, and source. That shift matters because a vape pen, an edible, and a home-grown product can carry very different patterns of dose timing, intoxication, and co-use with alcohol or nicotine. Youth cannabis harm reduction now sits at the intersection of emergency care, school health, and household storage. When students report easy access or home cultivation, the clinical response often needs to include parents, safer storage, and screening for other substance exposure, since cannabis use in adolescence rarely occurs in isolation. For adults, the most useful clinical signal may be modality variety itself. People who use several cannabis forms often have more complex substance use patterns, and that should change how clinicians ask about sleep, anxiety, pain, stimulant use, alcohol intake, and driving risk. Editorial Commentary *The adult data are a reminder that product variety is a clinical clue. When someone uses flower, vape, edibles, and concentrates, I think less about the product menu and more about the broader behavior pattern, because that mix often sits next to alcohol, nicotine, or stimulant use.* *For adolescents, access is the story. If cannabis is easy to get at home, through peers, or through local cultivation, the conversation has to include storage, supervision, and the family’s understanding of intoxication, not just whether the teen has tried cannabis.* *I also think these findings support a more careful intake. Asking about route, source, and co-use takes little time, and it often reveals the difference between occasional experimentation and a more complicated substance use picture.* What a Careful Reader Should Take Away Ask about cannabis route, source, and co-use, because those details carry real clinical meaning. In youth, focus on access and storage, and in adults, treat multiple product use as a prompt for broader substance screening. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🧸Children and Teens](https://cedclinic.com/ask)[🛡️Use Disorder](https://cedclinic.com/ask)[🛡️Safety](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Cannabis News & Regulatory Digest These studies point to a practical clinical theme: cannabis exposure is shaped by route, access, and co-use, and those details change risk assessment. The most useful reading question is whether the finding helps identify patients who need broader substance screening, safer storage counseling, or closer follow-up. ### Three Rules for Critical Reading **1. Separate route from exposure**The adult NSDUH analysis treats smoking, vaping, edibles, dabbing, lozenges, topicals, pills, and other forms as distinct behaviors. That matters because modality variety may mark heavier or more complex use patterns, while a single route may carry a different risk profile. **2. Read youth data through the lens of access**The ED review and the Thai school study both point toward availability as a driver of harm. Home cultivation, perceived accessibility, and adolescent ED presentations should be read as signals to ask about storage, supervision, and co-use with alcohol or nicotine. **3. Do not confuse association with causation**These are observational and review-level data, so they can identify patterns but cannot prove that cannabis products cause polysubstance use or emergency visits. The right clinical response is targeted screening and counseling, not overclaiming certainty. Key Evaluation Question Does the study show that cannabis route or access independently predicts harm after accounting for age, mental health, social setting, and prior substance use? The Patient Question If I use more than one cannabis product, or if cannabis is easy to get at home, what other substance use or safety issues should we screen for? The Bottom Line Route and access are clinically meaningful clues, but they are not proof of causation. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on Cannabis Use Behaviors and Associations with . #### What this means for patients If you use more than one cannabis product, that pattern may tell your clinician something important about your overall substance use risk. It is worth being specific about flower, vape, edibles, concentrates, and any other products, because route and variety can change the conversation. For teens and families, access matters as much as use. Cannabis stored at home, shared by peers, or grown in the household can raise the chance of early exposure, intoxication, and emergency care, so safer storage and open discussion are practical steps. Lens takeawayTell your clinician exactly which cannabis products you use and how easy they are to access. #### How to use this in practice A brief cannabis history should include route, frequency, source, and co-use with alcohol, nicotine, stimulants, and sedatives. The adult survey suggests that modality variety is a useful marker for broader polysubstance screening. In adolescents, ask about home cultivation, household storage, and peer access. Those details can guide counseling, caregiver involvement, and decisions about whether an ED visit or outpatient follow-up needs more urgent substance use assessment. In clinical practice, evaluating clinician factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayRoute, source, and co-use belong in every cannabis history, especially for youth. #### Safety signals to watch Multiple product use can mean more variable dosing, more frequent intoxication, and more opportunities for mixing with alcohol or other drugs. That combination raises concern for impaired driving, panic, vomiting, and accidental overuse, especially with edibles and concentrates. For youth, easy access at home or through peers should trigger a safety review. Locked storage, clear labeling, and caregiver awareness can reduce accidental ingestion and lower the chance of an avoidable emergency department visit. In clinical practice, evaluating safety factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayMore products and easier access both deserve a closer safety review. #### Policy implications These findings support policies that distinguish among cannabis product types rather than treating all use as identical. Public health messaging may need to address concentrates, edibles, and multi-product use separately from occasional single-route use. For youth, household access and school environment remain central policy targets. Prevention efforts that include storage standards, caregiver education, and school-based screening are more likely to match the risk patterns described here. In clinical practice, evaluating policy factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayPolicy works better when it targets product type, access, and youth exposure separately. #### What future studies should answer The next step is to test whether modality variety predicts later substance use disorder, ED visits, or functional harm after adjustment for baseline risk. Longitudinal designs would help separate cause from marker of risk. Youth studies should report standardized age bands, product types, co-ingestants, and access pathways. That would make it easier to compare school surveys, ED cohorts, and household-level prevention studies. In clinical practice, evaluating research factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayFuture work should track whether product variety predicts later harm over time. #### Where the evidence is weakest The adult survey cannot tell us whether multiple product use causes polysubstance use or simply travels with it. People who use several cannabis forms may differ in age, mental health, social setting, or prior drug exposure. The youth review and Thai school study are useful for pattern recognition, but their value depends on the quality of the underlying studies and local context. Without standardized measures, exact risk estimates remain uncertain. In clinical practice, evaluating skeptic factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayThese studies show association patterns, not proof of causation, providing structured guidance for routine clinical evaluations. #### What caregivers should notice If a teen can easily get cannabis at home, the household needs a storage and supervision reset. Locked storage, clear rules, and direct conversations about intoxication are practical steps that fit the risks described in the school and ED literature. Caregivers should also watch for changes in sleep, school performance, mood, and use of alcohol or nicotine. Cannabis use in adolescents often sits inside a broader behavior pattern, so a narrow focus on one product can miss the larger issue. In clinical practice, evaluating caregiver factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayCaregivers should lock cannabis away and ask about alcohol, nicotine, and peer access. #### Bottom-line clinical takeaway Cannabis route and access are not minor details, they are part of the risk assessment. Multiple product use in adults and easy access in youth both point toward broader screening and more specific counseling. The safest response is practical and specific: ask what is used, how it is obtained, who else is in the home, and whether alcohol or other drugs are part of the picture. That is where the clinical signal lives. In clinical practice, evaluating takeaway factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone. Lens takeawayAsk better questions about cannabis, because the details change the risk. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+Use+Behaviors+and+Associations+with+Home+Cultivation+and+Perceived+Accessibility+among+Secondary+School+Students+in+Songkhla%2C+Thailand&url=https%3A%2F%2Fcedclinic.com%2Fced-cannabis-product-type-tracks-with-polysubstan-2026-10-09%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-cannabis-product-type-tracks-with-polysubstan-2026-10-09%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+Use+Behaviors+and+Associations+with+Home+Cultivation+and+Perceived+Accessibility+among+Secondary+School+Students+in+Songkhla%2C+Thailand%20https%3A%2F%2Fcedclinic.com%2Fced-cannabis-product-type-tracks-with-polysubstan-2026-10-09%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: Substance use & misuse, BMC Emergency Medicine, Journal of Health Science and Medical Research](https://pubmed.ncbi.nlm.nih.gov/42854091/) Related Reading at CED ClinicContinue exploring the evidence[Adolescent Cannabis Use and Its Impact on Cognitive Development: Insights from the ABCD Study](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/) More on this topic: Long-term ABCD study findings on adolescent brain development, executive function, and early cannabis susceptibility. [More on this topic: Adolescent brain health](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[Prenatal Cannabis Use and Motivation to Quit: What a New Study Found](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) More on this topic: Dr. Caplan evaluates pregnant patients’ motivation to stop or reduce cannabis use, clinical cessation discussions, and quitline uptake barriers. [More on this topic: Prenatal quit motivation](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/) ## Frequently Asked Questions What is covered in this cannabis news & regulatory digest? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact [patient access](https://cedclinic.com/tsa-rules-on-cbd-gummies-travel-guidelines-2026/)? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).